Multiple drug resistance (MDR), referring to the resistance of cancer cells to a broad
spectrum of structurally and mechanistically unrelated drugs across membranes, severely …

Breast cancer affects approximately 1 in 8 women, and it is estimated that over 246,660
women in the USA will be diagnosed with breast cancer in 2016. Breast cancer mortality has …

Lung cancer causes the highest mortality compared to other cancers in the world according
to the latest WHO reports. Non-small cell lung cancer (NSCLC) contributes about 85% of …

Resistance to conventional and target specific antitumor drugs still remains one of the major
cause of treatment failure and patience death. This condition often involves ATP-binding …

This special issue of Drug Resistance Updates is dedicated to multidrug resistance protein 1
(MDR-1), 35 years after its discovery. While enormous progress has been made and our …

The use of oral anticancer drugs has increased during the last decade, because of patient
preference, lower costs, proven efficacy, lack of infusion-related inconveniences, and the …

Molecular targeting therapeutics, such as EGFR tyrosine kinase inhibitors (TKIs), are
important treatment strategies for lung cancer. Currently, the major challenge confronting …

Accumulating evidence suggests that various diseases, including many types of cancer,
result from alteration of subcellular protein localization and compartmentalization. Therefore …

Tyrosine kinase inhibitors (TKIs) are being increasingly used to treat various malignancies.
Although they were designed to target aberrant tyrosine kinases, they are also intimately …

PLX4032/vemurafenib is a first-in-class small-molecule BRAF V600E inhibitor with clinical
activity in patients with BRAF mutant melanoma. Nevertheless, drug resistance develops in …